The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
Open accessAbstract
Introduction Human epidermal growth factor receptor 2 gene (HER2 [also known as ERBB2]) alterations have been identified as oncogenic drivers and potential therapeutic targets in lung cancers. The molecular associations of HER2 gene amplification, mutation, and HER2 protein overexpression in lung cancers have not been distinctly defined. To explore these associations, Memorial Sloan Kettering Cancer Center and the University of Colorado combined their data on HER2 alterations in lung cancers.Methods Tumor specimens from 175 patients with lung adenocarcinomas and no prior targeted therapy were evaluated for the presence of HER2 amplification and mutation and HER2 protein overexpression. Amplification was assessed by fluorescence in situ hybridization (FISH) and defined as an HER2-to-chromosome enumeration probe 17 ratio of at least 2.0. Mutation was assessed by fragment analysis, mass spectrometry genotyping, and Sanger sequencing. Overexpression was assessed by immunohistochemical (IHC) staining. The frequencies of HER2 amplification and mutation and HER2 overexpression were calculated and their overlap examined.Results HER2 amplification was detected by FISH in 5 of 175 cases (3%). HER2 mutation was detected in 4 of 148 specimens (3%), including three identical 12-base pair insertions (p.A775_G776insYVMA) and a 9-base pair insertion, all in exon 20. None of the HER2-mutant cases was amplified. HER2 overexpression (2+ or 3+) on IHC staining was not detected in the 25 specimens available for testing, and negative IHC staining correlated with the negative results according to FISH.Conclusions HER2 mutations are not associated with HER2 amplification, thus suggesting a distinct entity and therapeutic target. HER2-positive lung cancer may not be an adequate term, and patient cohorts for the study of HER2-targeted agents should be defined by the specific HER2 alteration present.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ten ERBB2 mutations were detected, including 5 exon 20 insertions shown to confer sensitivity to ERBB2-targeted therapies (36).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710
Mazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668
Arcila, M. E., Chaft, J. E., Nafa, K., Roy-Chowdhuri, S., Lau, C., Zaidinski, M., Paik, P. K., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0912 · Cited by 505
Sholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430
Gatzemeier, U., Groth, G., Butts, C. A., van Zandwijk, N., Shepherd, F. A., Ardizzoni, A., Barton, C. M., Ghahramani, P., & Hirsh, V. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh031 · Cited by 388
Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334
Grève, J. D., Teugels, E., Geers, C., Decoster, L., Galdermans, D., Mey, J. D., Everaert, H., Umelo, I. A., Veld, P. I. '., & Schallier, D. C. C. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.01.008 · Cited by 272
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
Hirsch, F. R., Varella-Garcia, M., Franklin, W. A., Veve, R., Chen, L., Helfrich, B., Zeng, C., Barón, A. E., & Bunn, P. A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600286 · Cited by 253
Flagged first, then by citations
1 of the 16 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 289
Use of the GeneReader NGS System in a clinical pathology laboratory: a comparative study
Koitzsch, U., Heydt, C., Attig, H., Immerschitt, I., Merkelbach‐Bruse, S., Fammartino, A., Büttner, R., Kong, Y., & Odenthal, M. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204342 · Cited by 22
Xiao, F., Liu, N., Ma, X., Qin, J., Liu, Y., & Wang, X. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13670 · Cited by 22
Xiang, C., Ji, C., Cai, Y., Teng, H., Wang, Y., Zhao, R., Shang, Z., Guo, L., Chen, S., Lizaso, A., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01076-w · Cited by 22
Desai, A., Menon, S. P., & Dy, G. K. (2016) · PubMed Central · doi:10.28092/j.issn.2095-3941.2016.0008 · Cited by 22
Tafe, L. J., Pierce, K. J., Peterson, J. D., Abreu, F. D., Memoli, V. A., Black, C. C., Pettus, J. R., Marotti, J. D., Gutmann, E. J., Liu, X., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.07.010 · Cited by 21
Song, Z., Lv, D., Chen, S., Huang, J., Wang, L., Xu, S., Chen, H., Wang, G., & Lin, Q. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657283 · Cited by 21
Guan, S., Wu, C., Chiu, C., Luo, T., Wu, J., Liao, T.-Z., & Liu, S. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1550-3 · Cited by 20
Diagnostic and Predictive Immunohistochemistry for Non–Small Cell Lung Carcinomas
Hung, Y. P., & Sholl, L. M. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000206 · Cited by 21
Malapelle, U., Muscarella, L. A., Pisapia, P., & Rossi, A. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1732922 · Cited by 23
Chen, J. A., & Riess, J. W. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.32 · Cited by 21
Yin, Y., Yang, H., Liu, Z., Tan, J., Zhu, C., Chen, M., Zhou, R., Wang, L., & Qian, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s281765 · Cited by 20
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
Zhao, Y., Wang, S., Yang, Z., Dong, Y., Wang, Y., Zhang, L., Hu, H., & Han, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.665484 · Cited by 20
Zhang, G., Dong, R., Kong, D., Liu, B., Zha, Y., & Luo, M. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210708115406 · Cited by 20
Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016
Bunn, P. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4064 · Cited by 20
Efficacy of immunotherapy in KRAS -mutant non-small-cell lung cancer with comutations
Davis, A. P., Cooper, W. A., Boyer, M. J., Lee, J., Pavlakis, N., & Kao, S. (2021) · Immunotherapy · doi:10.2217/imt-2021-0090 · Cited by 20
Clinicopathologic features and treatment advances in cancers with HER2 alterations
Cen, S., Liu, Z., Pan, H., & Han, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188605 · Cited by 20
HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas
Ersoy, E., Cao, Q. J., & Otis, C. N. (2021) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000812 · Cited by 19
HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
Vathiotis, I. A., Charpidou, A. G., Gavrielatou, N., & Syrigos, K. N. (2021) · Pharmaceuticals · doi:10.3390/ph14121300 · Cited by 20
HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies
Ferrari, G., Rio, B. D., Novello, S., & Passiglia, F. (2024) · Cancers · doi:10.3390/cancers16112018 · Cited by 19
Auliac, J. B., Dô, P., Bayle, S., Doubre, H., Vinas, F., Letreut, J., Falchero, L., Hauss, P. A., Thomas, P. A., & CHOUAID, C. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01001-9 · Cited by 19
Tafe, L. J. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000244 · Cited by 19
A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models
Singh, S. S., Mattheolabakis, G., Gu, X., Withers, S. S., Dahal, A., & Jois, S. D. S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113312 · Cited by 19
Zhao, L., Fu, L., Xu, Z., Fan, R., Xu, R., Fu, R., Zou, S., Wang, C., Zhang, Y., Wang, J., et al. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10108 · Cited by 20
Targeting HER2 -Mutant NSCLC — The Light Is On
Passaro, A., & Peters, S. (2022) · New England Journal of Medicine · doi:10.1056/nejme2119442 · Cited by 19
Chinese expert consensus on the diagnosis and treatment of HER2 ‐altered non–small cell lung cancer
Zhang, S., Wang, W., Xu, C., Zhang, Y., Cai, X., Wang, Q., Song, Z., Li, Z., Yu, J., Zhong, W., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14743 · Cited by 17
Yu, J., Li, M., Liu, X., Wu, S., Li, R., Jiang, Y., Zheng, J., Li, Z., Xin, K., Xu, Z., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116522 · Cited by 22
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer
Nokin, M., Ambrogio, C., Nadal, E., & Santamaría, D. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.11.005 · Cited by 21
Yan, F., Rinn, K. J., Kullnat, J. A., Wu, A., Ennett, M. D., Scott, E. L., & Kaplan, H. G. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7006 · Cited by 19
Du, Y., Feng, R., Wu, T., Xue, D. Q., Jia, H., Leng, D., Ju, H., & Wei, Q. L. (2025) · Journal of Analysis and Testing · doi:10.1007/s41664-025-00400-y · Cited by 17
Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung
Bernicker, E., Miller, R. A., & Cagle, P. T. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.019182 · Cited by 17
Posada, J. M., Yakirevich, E., Kamat, A. M., Sood, A., Jacob, J. M., Bratslavsky, G., Grivas, P. D., Spiess, P. E., Li, R., Necchi, A., et al. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100424 · Cited by 17
Lee, Y., Lee, B., Choi, Y., Kang, D., & Han, J. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100490 · Cited by 19
New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2
Olmedo, M. E., Cervera, R., Cabezón‐Gutiérrez, L., Lage, Y., de la Fuente, E. C., Rueda, A. G., Mielgo-Rubio, X., Trujillo-Reyes, J. C., & Couñago, F. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i4.276 · Cited by 19
Tan, A. C., Saw, S. P. L., Chen, J., Lai, G. G. Y., Hlaing, N. O., Takano, A. M., Lau, D. P., Yeong, J. P.-S., Tan, G. S., Lim, K. H., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00278 · Cited by 18
silva, J. D., Jouida, A., Ancel, J., Dalstein, V., Routhier, J., Delépine, G., Cutrona, J., Jonquet, A., Dewolf, M., Birembaut, P. L., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5439 · Cited by 16
A pharmacological exploration of targeted drug therapy in non-small cell lung cancer
Jayan, A. P., Anandu, K. R., Madhu, K., & Nirmala, S. V. (2022) · Medical Oncology · doi:10.1007/s12032-022-01744-6 · Cited by 16
Denis, M. G., & Bennouna, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s218751 · Cited by 16
Zhou, T., Mahn, R., Möhring, C., Sadeghlar, F., Meyer, C. H., Toma, M. I., Kreppel, B., Essler, M., Glowka, T. R., Matthaei, H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.933943 · Cited by 18
Zhao, S., Xian, X., Tian, P., Li, W., Wang, K., & Li, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633522 · Cited by 15
Proteoformics: Current status and future perspectives
Fang, Z., Zhang, Y., Feng, X., Li, N., Chen, L., & Zhan, X. (2025) · Journal of Proteomics · doi:10.1016/j.jprot.2025.105524 · Cited by 18
Fan, K., Wang, J., Shen, S., Ni, X., Gong, Z., Zheng, B., Sun, W., Suo, T., Liu, H., Ni, X., et al. (2022) · Medical Oncology · doi:10.1007/s12032-021-01568-w · Cited by 14
Bontoux, C., Benzaquen, J., Hofman, V., Heeke, S., Hannetel, P., Capela-Brosseau-Laborde, P., Marquette, C., Ilié, M., & Hofman, P. M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101651 · Cited by 14
Loeffler, E., Ancel, J., Dalstein, V., Deslée, G., Polette, M., & Nawrocki‐Raby, B. (2023) · Life · doi:10.3390/life14010064 · Cited by 15
Ren, Y., Cao, L., You, M., Ji, J., Gong, Y. M., Ren, H., Xu, F., Guo, H., Hu, J., & Li, Z. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116774 · Cited by 14
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies
Reinhorn, D. J., Moskovitz, M. T., Tap, W. D., & Li, B. T. (2025) · Cancer · doi:10.1002/cncr.35780 · Cited by 14
Han, Y., Xiong, Y., Lu, T., Chen, R., Liu, Y., Tang, H. J., Geng, R., & Wang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1121708 · Cited by 13
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Abdayem, P., & Planchard, D. (2021) · European Respiratory Review · doi:10.1183/16000617.0294-2020 · Cited by 14
Ganti, A. K., Rothe, M., Mangat, P. K., Garrett-Mayer, E. S., Dib, E. G., Duvivier, H. L., Ahn, E. R., Behl, D., Borghaei, H., Balmanoukian, A. S., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00041 · Cited by 13
Zhang, P., Nie, X., Wang, B., & Li, L. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12889 · Cited by 13
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach
Adesoye, T., Dumbrava, E. E. I., Raghav, K. P. S., Şahin, A. A., Chen, H., Lee, S. S., Javle, M. M., Pant, S., Alhalabi, O., Le, X., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1982 · Cited by 17
Hayashi, T., Kohsaka, S., Takamochi, K., Kishikawa, S., Ikarashi, D., Sano, K., Hara, K., Onagi, H., Suehara, Y., Takahashi, F., et al. (2020) · Histopathology · doi:10.1111/his.14311 · Cited by 12
CT features of HER2-mutant lung adenocarcinomas
Sawan, P., Plodkowski, A. J., Li, A. E., Li, B. T., Drilon, A. E. D. C., Capanu, M., & Ginsberg, M. S. (2018) · Clinical Imaging · doi:10.1016/j.clinimag.2018.05.028 · Cited by 12
Sartori, G., Belluomini, L., Lombardo, F., Avancini, A., Trestini, I., Vita, E., Tregnago, D., Menis, J., Bria, E., Milella, M., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1776119 · Cited by 12
Hofman, P. M. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2020015 · Cited by 12
Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations
Ni, J., & Zhang, L. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s312820 · Cited by 12
Verzè, M., Minari, R., Gnetti, L., Bordi, P., Leonetti, A., Cosenza, A., Ferri, L., Majori, M., Filippo, M. D., Buti, S., et al. (2021) · Cancers · doi:10.3390/cancers13215403 · Cited by 12
Cohen, D. H., Otakeno, S., Previc, F. H., & Ercoline, W. R. (2001) · PubMed · Cited by 12
Molecular Diagnostics in Non-Small Cell Lung Carcinoma
Sholl, L. M. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-3399564 · Cited by 11
Treatment of Rare Mutations in Patients with Lung Cancer
Taha, T., Khoury, R., Brenner, R. M., Nasrallah, H., Shofaniyeh, I., Yousef, S., & Agbarya, A. (2021) · Biomedicines · doi:10.3390/biomedicines9050534 · Cited by 11
Wu, R., Yuan, B., Li, C., Wang, Z., Song, Y., & Liu, H. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3265 · Cited by 11
Fluorescent In Situ Hybridization in Surgical Pathology Practice
Gupta, R., Cooper, W. A., Selinger, C. I., Mahar, A. M., Anderson, L. A., Buckland, M. E., & O'Toole, S. A. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000194 · Cited by 11
Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates
Kim, J., Kim, H. S., Nam, M., & Chae, Y. K. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10274-2 · Cited by 12
Wang, Q., Mao, Z., Li, W., Wang, S., Wang, L., Chen, L., Yang, Z., Fu, X., Jiang, P., Bai, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1042072 · Cited by 10
Karsaneh, O. A. A., Anber, A. A., Alqudah, M. A., Al-Mustafa, S., AlMa’aitah, H., & Sughayer, M. A. (2023) · Diagnostic Pathology · doi:10.1186/s13000-023-01364-2 · Cited by 10
Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation
Wang, J., Wen, Y., Ding, G., Ding, P., Zhang, L., Liu, J., Zhang, T., & Yang, L. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1449611 · Cited by 10
Chatziandreou, I., Psaraki, A., Paschidis, K., Lazaris, A. C., & Saetta, A. A. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153412 · Cited by 10
Zheng, S., Chen, R., Zhang, L., Tan, L., Li, L., Long, F., & Wang, T. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116702 · Cited by 11
Tian, X., Esmaeili, H. A., Minich, D., Seitz, F., Roessner, P. M., Wind, S., Grempler, R., Gan, G., Chan, T. S., Mahmoudi, M., et al. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4641 · Cited by 9
Liu, J., Yu, J., Yu, J., Ren, Q., Cai, Y., Chen, D., & Song, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06589-x · Cited by 10
Advances in mammalian, plant, and bacterial-derived extracellular vesicles for cancer therapy
Nie, X., Li, Q., Fatima, H., Wang, Y., Meng, F., Xie, J., & Nie, S. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.168637 · Cited by 9
Bao, J., Zhang, W., Zhou, W., Lv, M., Lu, C., & Yu, H. (2020) · Talanta · doi:10.1016/j.talanta.2020.120918 · Cited by 9
Chen, J., Xu, C., Wang, Q., Lv, J., Lu, W., Zhang, Y., Yao, Y., Gu, X., Wu, G., Hao, Y., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107315 · Cited by 9
Buhmeida, A. S., Assidi, M., Al-Maghrabi, J. A., Dallol, A., Sibiany, A., Al-Ahwal, M. S., Chaudhary, A., Abuzenadah, A. M., & Al-Qahtani, M. H. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1439054 · Cited by 9
Adoptive immune cell therapy for colorectal cancer
Liu, C., Liu, N., Zhang, T., & Tu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557906 · Cited by 8
Shan, J., Ruan, J., Tan, Y., Li, Y., Chen, S., Du, M., & Wang, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s271999 · Cited by 8
Physiologically driven nanodrug delivery system for targeted lung cancer treatment
Zhang, S., Li, X., Liu, Y., Li, H., & Zhang, Z. (2024) · Exploration of Medicine · doi:10.37349/emed.2024.00221 · Cited by 9
Yamaoka, T., Tsurutani, J., Sagara, H., & Ohmori, T. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-578 · Cited by 8
Non-amplification genetic alterations of HER2 gene in non-small cell lung carcinoma
Mehta, A., Nathany, S., Tripathi, R., Sharma, S. K., Saifi, M., & Batra, U. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206730 · Cited by 8
Piha-Paul, S. A., Tseng, C., Tran, H. T., Gao, M., Karp, D. D., Subbiah, V., Tsimberidou, A. M., Kawedia, J. D., Fu, S., Pant, S., et al. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04545-4 · Cited by 7
Thavaneswaran, S., Lin, F. P. Y., Grady, J. P., Espinoza, D., Huang, M., Chinchen, S., Sebastian, L. T., Kansara, M., Mersiades, T., Lee, C. K., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00698-4 · Cited by 7
Insights of affinity-based probes for target identification in drug discovery
Wang, H., Liu, L., Zhang, Z., Li, C., Wang, K., Gao, J., Hu, Q., Wang, W., & Li, H. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117711 · Cited by 7
Bispecific antibody for lung cancer: mechanisms and clinical insights
Chen, W., Zhou, A., & Zhou, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1572802 · Cited by 7
Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer
Ekyalongo, R., Yamaoka, T., & Tsurutani, J. (2025) · Biomolecules · doi:10.3390/biom15101443 · Cited by 7
ERBB2 Amplification in NSCLC: How Many Faces?
Shih, J. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.02.001 · Cited by 7
Bruno, R., Alì, G., Poma, A. M., & Fontanini, G. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-20-72 · Cited by 7
Wang, M., Zhang, D., Wang, G., Xia, J., Chen, S., Li, S., Xu, Y., Wang, Q., & Li, W. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.004 · Cited by 7
Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan
Yun, K. M., & Bazhenova, L. A. (2023) · BMJ Case Reports · doi:10.1136/bcr-2022-253260 · Cited by 7
Yang, L., Luo, X.-Z., Xie, L., Lei, X.-Z., & Zhu, J. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-95 · Cited by 6
Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer
Guo, H., Xu, Z., Li, K., Guo, C., Lin, F., Pu, Q., & Wang, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1787148 · Cited by 7
Zhuo, X., Guo, H., Ma, J., Lai, J., Liu, L., Yin, K., Zhao, J., Wang, J., Jiang, F., Xu, W., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04196-7 · Cited by 6
Daoud, A., & Chu, Q. S.-C. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00222 · Cited by 6
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
Toma, A. D., Russo, G. L., Signorelli, D., Pagani, F., Randon, G., Galli, G., Prelaj, A., Ferrara, R., Proto, C., Ganzinelli, M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103299 · Cited by 6
Wang, H., He, Y., Zhao, W., & Tong, Z. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001369 · Cited by 7
ERBB2 exon 20 insertions are rare in Brazilian non‐small cell lung cancer
Cavagna, R. D. O., Zaniolo, B. G., de Paula, F. E., Berardinelli, G. N., Santana, I. V. V., da Silva, E. C. A., Dias, J. M., Jacinto, A. A., Oliveira, R. E. N. D. N., Marchi, P. D., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14605 · Cited by 6
Aberrations in the glycosylation of receptor tyrosine kinases: A focus on lung adenocarcinoma
Dmitrieva, A. M., Kocak, I. G., & Meder, L. (2025) · CytoJournal · doi:10.25259/cytojournal_21_2025 · Cited by 6
Bharadwaj, S., Mierzwicka, J. M., Vaňková, L., & Malý, P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02410-w · Cited by 7
Raftery, N. B., Ward, M. P., Ravi, N., Reynolds, J. V., Elliott, J. A., & Donohoe, C. L. (2025) · Cancers · doi:10.3390/cancers17243987 · Cited by 6
Bian, D. J. H., Cohen, S. F., Lazaratos, A.-M., Bouganim, N., & Dankner, M. (2024) · Current Oncology · doi:10.3390/curroncol31100471 · Cited by 5
Ma, J., Li, X., Zhang, Q., Li, N., Sun, S., Zhao, S., Zhao, Z., & Li, M. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101444 · Cited by 5
Path Less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer
Lim, S. M., Lee, J. B., Oya, Y., Nützinger, J., & Soo, R. A. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00273 · Cited by 6
Metadata
- Authors
- Li, B. T., Ross, D. S., Aisner, D. L., Chaft, J. E., Hsu, M., Kako, S. L., Kris, M. G., Varella-Garcia, M., & Arcila, M. E.
- Affiliations
- The University of Sydney (AU)
- Memorial Sloan Kettering Cancer Center (US)
- University of Colorado Anschutz (US)
- Corresponding author
- Li, Bob T.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 11
- Issue
- 3
- Pages
- 414-419
- ISSN
- 1556-0864 (ISSN-L)
- PMC
- PMC4698879
- OpenAlex
- W2262992387
- Cited by
- 286
- References
- 16
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 23 · 2023: 31 · 2022: 32 · 2021: 42 · 2020: 39 · 2019: 23 · 2018: 23 · 2017: 12 · 2016: 7
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (1RC2 CA148394, P50CA058187, P30 CA046934, P30 CA008748)
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- HER2, HER2 amplification, HER2 mutation, HER2 overexpression, lung adenocarcinoma, HER2 exon 20 insertion, HER2-targeted therapy, molecular subtyping
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Aged, Female, Gene Amplification, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, In Situ Hybridization, Fluorescence, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Genes, erbB-2, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
